Compare HP & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | LIVN |
|---|---|---|
| Founded | 1920 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 1994 | 2015 |
| Metric | HP | LIVN |
|---|---|---|
| Price | $34.55 | $79.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $34.17 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 1.3M | 698.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $3,746,013,000.00 | N/A |
| Revenue This Year | $9.50 | $9.79 |
| Revenue Next Year | $3.34 | $6.63 |
| P/E Ratio | ★ N/A | $198.03 |
| Revenue Growth | ★ 35.89 | N/A |
| 52 Week Low | $15.17 | $41.02 |
| 52 Week High | $41.82 | $85.27 |
| Indicator | HP | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 48.50 |
| Support Level | $32.88 | $61.63 |
| Resistance Level | $34.67 | $80.96 |
| Average True Range (ATR) | 1.10 | 2.15 |
| MACD | 0.39 | -0.73 |
| Stochastic Oscillator | 96.49 | 19.58 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.